气道炎症检测与生物影像引导的综合策略实现重症哮喘临床缓解
该研究评估以临床评估、气道生理学、气道炎症检测和生物影像引导的综合个体化策略,在178例重症哮喘患者中实现24个月临床缓解的效果。结果显示,基于三项主要标准的临床缓解率为66.3%,纳入FEV1下降≤5%时为61.6%,而最严格标准下仅29.1%;残余疾病活动主要由气道感染和气道高反应性驱动,而非2型炎症。
要点
- 综合个体化策略下66.3%重症哮喘患者达24个月临床缓解(三项主要标准)。
- 最严格标准(ACQ-5≤0.75且FEV1≥80%)下临床缓解率降至29.1%。
- 残余疾病活动主要源于气道感染和气道高反应性,而非2型炎症。
核心结论
- 采用综合生物标志物和个体化病理生物学管理策略,重症哮喘患者可实现较高比例的临床缓解,但缓解率取决于所用定义。
- 反复气道感染、黏液和气道高反应性仍是重症哮喘的关键未满足需求。
研究设计与样本
- 研究纳入178例重症哮喘患者,评估综合个体化治疗策略在24个月内实现临床缓解的效果。
- 治疗策略包括抗炎治疗、生物制剂、抗生素、免疫调节剂和支气管热成形术,由临床评估、气道生理学、气道炎症检测和生物影像引导。
主要发现
- 88.2%患者接受生物制剂单用或联合其他策略治疗,20.2%接受抗生素、高渗盐水或免疫球蛋白治疗,9%在控制炎症后接受支气管热成形术。
- 24个月后,89.9%患者无急性发作,83.1%停用口服糖皮质激素,78.1%症状部分或良好控制,85.4%肺功能保持。
- 基于三项主要标准的临床缓解率为66.3%,纳入FEV1较基线下降≤5%时为61.6%,最严格标准(ACQ-5≤0.75且FEV1≥80%)下为29.1%。
关键数值与推荐
- 临床缓解定义为24个月无急性发作、未使用口服糖皮质激素、症状部分或良好控制,伴或不伴肺功能标准。
- 三项主要标准下临床缓解率为66.3%,纳入FEV1下降≤5%时为61.6%,最严格标准下为29.1%。
临床怎么用
- 对重症哮喘患者可采用由气道炎症检测和生物影像引导的综合个体化策略以追求临床缓解。
- 临床缓解评估需注意定义差异,最严格标准下缓解率明显降低。
- 对残余气道感染和气道高反应性需持续关注和干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Clinical remission is a multicomponent treatment goal in severe asthma. However, only about 30% of patients achieve clinical remission when treatment decisions are guided using blood eosinophil counts and fractional exhaled nitric oxide concentrations. Objectives: To assess the effectiveness of a comprehensive, individualized treatment strategy in achieving clinical remission over 24 months in patients with severe asthma. Methods: Treatment strategies-including antiinflammatory therapies, biologics, antibiotics, immunomodulators, and bronchial thermoplasty-were guided by clinical assessment, airway physiology, airway inflammometry, and bioimaging. Clinical remission was defined as no exacerbations for 24 months, no oral corticosteroid use, and partly/well-controlled symptoms, with or without lung function criteria. Measurements and Main Results: A total of 178 patients with severe asthma were evaluated. Of these, 88.2% were treated with biologics alone or in combination with other strategies; 20.2% were treated with antibiotics, hypertonic saline, and/or immunoglobulins; and 9% underwent bronchial thermoplasty after controlling the inflammatory component. After 24 months, 89.9% of patients were exacerbation-free, 83.1% were oral corticosteroid-free, 78.1% had partly/well-controlled symptoms, and 85.4% had preserved lung function. Clinical remission was achieved in 66.3% of patients based on the three primary criteria and in 61.6% when including FEV1% decline ⩽5% from baseline. However, when the most stringent criteria were applied (five-point Asthma Control Questionnaire ⩽0.75 and FEV1 ⩾80%), the clinical remission rate was 29.1%. Residual disease activity was driven primarily by airway infections and airway hyperresponsiveness rather than type 2 inflammation. Conclusions: By using a comprehensive set of biomarkers and a management strategy tailored to individual pathobiology, a high proportion of patients with severe asthma can achieve clinical remission, depending on the definitions used. Nonetheless, recurrent airway infections, mucus, and airway hyperresponsiveness remain key unmet needs in severe asthma.
引用
- Nolasco, Kjarsgaard, Lauks, et al. Clinical Remission by a Comprehensive Severe Asthma Management Strategy Guided by Airway Inflammometry and Bioimaging. Am J Respir Crit Care Med. 2025. PMID: 40540629. doi:10.1164/rccm.202412-2438OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。